PATENT CLAIM ANALYSIS

Application Number: 16186879
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-02
Patent Classification: ["514", "001400"]

Abstract:
The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.

Claim (Index 28):
A method according to  claim 27 , wherein cyclo[Hydantoin(C(O)-(Cys-D-Ala))-His-D-Phe-Arg-Trp-Cys]-NH 2 , (SEQ ID NO:1) or a pharmaceutically acceptable salt thereof is administered.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.46875
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12602010', '14024961', '13074565', '11988468', '15055873']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8804704287262649
- 35 USC 102 Novelty (BERT): 0.6550688470756949
- Combined Prediction Score: 0.857930270561208
- Mean Citation Score: 625.486862
- Max Citation Score: 672.6033
- Similarity Product: 600.9234014116645

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test